Advertisement

Efficacy and Safety of Ticagrelor Compared with Clopidogrel in Patients with End-Stage Renal Disease with Acute Myocardial Infarction

  • Chien-Ho Lee
  • Tzu-Hsien Tsai
  • Cheng-Jui Lin
  • Shu-kai Hsueh
  • Wen-Jung Chung
  • Cheng-I ChengEmail author
Original Research Article

Abstract

Objective

This study investigated the efficacy and safety of ticagrelor compared with clopidogrel in patients with end-stage renal disease (ESRD) and acute myocardial infarction (AMI).

Methods

We retrospectively enrolled patients who had received regular dialysis and had undergone percutaneous coronary intervention (PCI) for AMI at our hospital between January 2013 and December 2016. Outcomes analyzed included cardiovascular death, death from any cause, MI, stroke, and bleeding events.

Result

Patients were allocated to the ticagrelor group (N = 74) or the clopidogrel group (N = 116) according to the treatment they had received. No statistically significant differences were found between the groups in terms of in-hospital primary endpoint (composite of cardiovascular death, MI, and stroke: 12.2% and 15.5% for ticagrelor and clopidogrel, respectively; p = 0.518), secondary endpoint, or any bleeding events (39.2 vs. 34.5%; p = 0.511). No statistically significant differences were found for the 1-year primary endpoint (p = 0.424), secondary endpoint, and any bleeding events (p = 0.663). Risk factors for in-hospital cardiovascular death were shock and cardiopulmonary resuscitation at initial AMI presentation, lack of beta-blocker use, and in-hospital gastrointestinal bleeding. Risk factors for 1-year cardiovascular death were shock at initial AMI presentation and lack of beta-blocker use. Only respiratory failure was a risk factor for in-hospital and 1-year gastrointestinal bleeding.

Conclusion

In patients with ESRD and AMI, ticagrelor resulted in numerically fewer but statistically nonsignificant rates of in-hospital and 1-year cardiovascular events with no significant increase in bleeding events compared with clopidogrel.

Notes

Acknowledgements

The authors thank the Biostatistics Center, Kaohsiung Chang Gung Memorial Hospital, for their statistical work.

Compliance with Ethical Standards

Funding

No external funding was used in the preparation of this manuscript.

Conflicts of interest

C-HL, T-HT, C-JL, S-KH, W-JC, and C-IC have no conflicts of interest that are directly relevant to the content of this article.

References

  1. 1.
    Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68(10):1082–115.CrossRefGoogle Scholar
  2. 2.
    Kim C, Shin DH, Ahn CM, Kim JS, Kim BK, Ko YG, et al. The use pattern and clinical impact of new antiplatelet agents including Prasugrel and Ticagrelor on 30-day outcomes after acute myocardial infarction in Korea: Korean health insurance review and assessment data. Korean Circ J. 2017;47(6):888–97.CrossRefGoogle Scholar
  3. 3.
    Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57.CrossRefGoogle Scholar
  4. 4.
    Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267–315.CrossRefGoogle Scholar
  5. 5.
    Gremmel T, Muller M, Steiner S, Seidinger D, Koppensteiner R, Kopp CW, et al. Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy. Nephrol Dial Transpl. 2013;28(8):2116–22.CrossRefGoogle Scholar
  6. 6.
    Park SH, Kim W, Park CS, Kang WY, Hwang SH, Kim W. A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol. 2009;104(9):1292–5.CrossRefGoogle Scholar
  7. 7.
    Guo LZ, Kim MH, Shim CH, Choi SY, Serebruany VL. Impact of renal impairment on platelet reactivity and clinical outcomes during chronic dual antiplatelet therapy following coronary stenting. Eur Heart J Cardiovasc Pharmacother. 2016;2(3):145–51.CrossRefGoogle Scholar
  8. 8.
    Muller C, Caillard S, Jesel L, El Ghannudi S, Ohlmann P, Sauleau E, et al. Association of estimated GFR with platelet inhibition in patients treated with clopidogrel. Am J Kidney Dis. 2012;59(6):777–85.CrossRefGoogle Scholar
  9. 9.
    Capodanno D, Angiolillo DJ. Antithrombotic therapy in patients with chronic kidney disease. Circulation. 2012;125(21):2649–61.CrossRefGoogle Scholar
  10. 10.
    Montalescot G, Silvain J. Ticagrelor in the renal dysfunction subgroup: subjugated or substantiated? Circulation. 2010;122(11):1049–52.CrossRefGoogle Scholar
  11. 11.
    James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the platelet inhibition and patient outcomes (PLATO) trial. Circulation. 2010;122(11):1056–67.CrossRefGoogle Scholar
  12. 12.
    Blicher TM, Hommel K, Kristensen SL, Torp-Pedersen C, Madsen M, Kamper AL, et al. Benefit of clopidogrel therapy in patients with myocardial infarction and chronic kidney disease—a Danish nation-wide cohort study. J Am Heart Assoc. 2014;3(4):e001116.CrossRefGoogle Scholar
  13. 13.
    Kaw D, Malhotra D. Platelet dysfunction and end-stage renal disease. Semin Dial. 2006;19(4):317–22.CrossRefGoogle Scholar
  14. 14.
    Summaria F, Giannico MB, Talarico GP, Patrizi R. Antiplatelet therapy in hemodialysis patients undergoing percutaneous coronary interventions. Nephro-Urol Mon. 2015;7(4):e28099.CrossRefGoogle Scholar
  15. 15.
    Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Cannon CP, et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation. 2010;121(3):357–65.CrossRefGoogle Scholar
  16. 16.
    Gupta T, Paul N, Kolte D, Harikrishnan P, Khera S, Aronow WS, et al. Association of chronic renal insufficiency with in-hospital outcomes after percutaneous coronary intervention. J Am Heart Assoc. 2015;4(6):e002069.Google Scholar
  17. 17.
    Tsai TT, Messenger JC, Brennan JM, Patel UD, Dai D, Piana RN, et al. Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI Registry—CMS claims database. J Am Coll Cardiol. 2011;58(18):1859–69.CrossRefGoogle Scholar
  18. 18.
    Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2002;39(7):1113–9.CrossRefGoogle Scholar
  19. 19.
    Jeong KH, Cho JH, Woo JS, Kim JB, Kim WS, Lee TW, et al. Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study. Am J Kidney Dis. 2015;65(6):916–24.CrossRefGoogle Scholar
  20. 20.
    Alexopoulos D, Panagiotou A, Xanthopoulou I, Komninakis D, Kassimis G, Davlouros P, et al. Antiplatelet effects of prasugrel vs double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. J Thromb Haemost. 2011;9(12):2379–85.CrossRefGoogle Scholar
  21. 21.
    Alexopoulos D, Xanthopoulou I, Plakomyti TE, Goudas P, Koutroulia E, Goumenos D. Ticagrelor in clopidogrel-resistant patients undergoing maintenance hemodialysis. Am J Kidney Dis. 2012;60(2):332–3.CrossRefGoogle Scholar
  22. 22.
    Levine GN, Jeong YH, Goto S, Anderson JL, Huo Y, Mega JL, et al. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol. 2014;11(10):597–606.CrossRefGoogle Scholar
  23. 23.
    Kang HJ, Clare RM, Gao R, Held C, Himmelmann A, James SK, et al. Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: a retrospective analysis from the platelet inhibition and patient outcomes (PLATO) trial. Am Heart J. 2015;169(6):899.e1–905.e1.CrossRefGoogle Scholar
  24. 24.
    Park KH, Jeong MH, Ahn Y, Ahn TH, Seung KB, Oh DJ, et al. Comparison of short-term clinical outcomes between ticagrelor versus clopidogrel in patients with acute myocardial infarction undergoing successful revascularization; from Korea Acute Myocardial Infarction Registry-National Institute of Health. Int J Cardiol. 2016;15(215):193–200.CrossRefGoogle Scholar
  25. 25.
    Misumida N, Aoi S, Kim SM, Ziada KM, Abdel-Latif A. Ticagrelor versus clopidogrel in East Asian patients with acute coronary syndrome: systematic review and meta-analysis. Cardiovasc Revasc Med Incl Mol Interv. 2018;19:689–94.CrossRefGoogle Scholar
  26. 26.
    Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK, Cornel JH, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2011;32(23):2933–44.CrossRefGoogle Scholar
  27. 27.
    Collette C, Clerc-Urmes I, Laborde-Casterot H, Frimat L, Ayav C, Peters N, et al. Antiplatelet and oral anticoagulant therapies in chronic hemodialysis patients: prescribing practices and bleeding risk. Pharmacoepidemiol Drug Safety. 2016;25(8):935–43.CrossRefGoogle Scholar
  28. 28.
    Tsai TH, Chua S, Hussein H, Leu S, Wu CJ, Hang CL, et al. Outcomes of patients with Killip class III acute myocardial infarction after primary percutaneous coronary intervention. Crit Care Med. 2011;39(3):436–42.CrossRefGoogle Scholar
  29. 29.
    Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol. 2003;42(2):201–8.CrossRefGoogle Scholar
  30. 30.
    Grall S, Biere L, Le Nezet M, Bouvier JM, Lucas-Chauvelon P, Richard C, et al. Relationship between beta-blocker and angiotensin-converting enzyme inhibitor dose and clinical outcome following acute myocardial infarction. Circ J. 2015;79(3):632–40.CrossRefGoogle Scholar
  31. 31.
    Marcolino MS, Simsek C, de Boer SP, van Domburg RT, van Geuns RJ, de Jaegere P, et al. Short- and long-term major adverse cardiac events in patients undergoing percutaneous coronary intervention with stenting for acute myocardial infarction complicated by cardiogenic shock. Cardiology. 2012;121(1):47–55.CrossRefGoogle Scholar
  32. 32.
    Shah RU, de Lemos JA, Wang TY, Chen AY, Thomas L, Sutton NR, et al. Post-hospital outcomes of patients with acute myocardial infarction with cardiogenic shock: findings from the NCDR. J Am Coll Cardiol. 2016;67(7):739–47.CrossRefGoogle Scholar
  33. 33.
    Shalev A, Zahger D, Novack V, Etzion O, Shimony A, Gilutz H, et al. Incidence, predictors and outcome of upper gastrointestinal bleeding in patients with acute coronary syndromes. Int J Cardiol. 2012;157(3):386–90.CrossRefGoogle Scholar
  34. 34.
    Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114(8):774–82.CrossRefGoogle Scholar
  35. 35.
    Lin TH, Lai WT, Kuo CT, Hwang JJ, Chiang FT, Chang SC, et al. Additive effect of in-hospital TIMI bleeding and chronic kidney disease on 1-year cardiovascular events in patients with acute coronary syndrome: data from Taiwan Acute Coronary Syndrome Full Spectrum Registry. Heart Vessel. 2015;30(4):441–50.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Cardiology, Department of Internal MedicineKaohsiung Chang Gung Memorial HospitalKaohsiungTaiwan

Personalised recommendations